Thermo Fisher Scientific Inc. $TMO Shares Sold by Natural Investments LLC

Key Points

• Natural Investments LLC reduced its stake in Thermo Fisher Scientific by 10.2% during the second quarter, holding now 4,783 shares valued at approximately $1.94 million.
• Thermo Fisher Scientific reported a Q2 earnings per share of $5.36, exceeding analysts' expectations of $5.22 and a revenue of $10.86 billion, marking a 2.9% increase year-over-year.
• Research analysts have generally given the stock a consensus rating of "Moderate Buy" with an average price target of $593.43, indicating optimism for the company's future performance.

Natural Investments LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 10.2% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 4,783 shares of the medical research company's stock after selling 541 shares during the period. Natural Investments LLC's holdings in Thermo Fisher Scientific were worth $1,939,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in TMO. CBIZ Investment Advisory Services LLC increased its holdings in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after buying an additional 33 shares during the last quarter. Anderson Financial Strategies LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $30,000. Keystone Global Partners LLC acquired a new stake in shares of Thermo Fisher Scientific during the 1st quarter worth $31,000. DiNuzzo Private Wealth Inc. increased its holdings in shares of Thermo Fisher Scientific by 406.7% during the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock worth $31,000 after buying an additional 61 shares during the last quarter. Finally, HighMark Wealth Management LLC boosted its position in Thermo Fisher Scientific by 140.6% during the 2nd quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company's stock worth $31,000 after purchasing an additional 45 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Performance

NYSE:TMO opened at $524.95 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a 50-day moving average of $488.68 and a two-hundred day moving average of $448.39. The stock has a market cap of $198.23 billion, a P/E ratio of 30.36, a PEG ratio of 2.90 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period in the prior year, the company posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Insider Transactions at Thermo Fisher Scientific

In other news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the transaction, the chief executive officer directly owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 30,066 shares of company stock valued at $14,182,963. Insiders own 0.33% of the company's stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research reports. Evercore ISI upped their price target on shares of Thermo Fisher Scientific from $525.00 to $590.00 and gave the stock an "outperform" rating in a research report on Tuesday. Wall Street Zen raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday, October 4th. JPMorgan Chase & Co. upped their price target on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an "overweight" rating in a research report on Thursday. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research report on Thursday, July 24th. Finally, Redburn Partners set a $580.00 price target on shares of Thermo Fisher Scientific in a research report on Wednesday. Sixteen research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $593.43.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.